Associated High Confidence AOPs |
---|
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:6 | Antagonist binding to PPARα leading to body-weight loss | Symptom | WPHA/WNT Endorsed | 0.12 | KE:1528 | Fatty Acid Beta Oxidation, Decreased |
AOP:15 | Alkylation of DNA in male pre-meiotic germ cells leading to heritable mutations | Genetic Disease | WPHA/WNT Endorsed | 0.25 | KE:155 | Inadequate DNA repair |
AOP:16 | Acetylcholinesterase inhibition leading to acute mortality | Unclassified | Under Development | 0.14 | KE:445 | Respiratory distress/arrest |
AOP:18 | PPARα activation in utero leading to impaired fertility in males | Reproductive System Disease | Under Review | 0.12 | KE:413 | Reduction, Testosterone synthesis in Leydig cells |
AOP:21 | Aryl hydrocarbon receptor activation leading to early life stage mortality, via increased COX-2 | Unclassified | WPHA/WNT Endorsed | 0.2 | KE:317 | Altered, Cardiovascular development/function |
AOP:23 | Androgen receptor agonism leading to reproductive dysfunction (in repeat-spawning fish) | Unclassified | WPHA/WNT Endorsed | 0.1 | KE:274 | Reduction, Testosterone synthesis by ovarian theca cells |
AOP:27 | Cholestatic Liver Injury induced by Inhibition of the Bile Salt Export Pump (ABCB11) | Gastrointestinal System Disease | Under Development | 0.25 | KE:149 | Increase, Inflammation |
KE:1115 | Increase, Reactive oxygen species | |||||
AOP:36 | Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to Steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.12 | KE:179 | Decreased, Mitochondrial fatty acid beta-oxidation |
AOP:37 | PPARα activation leading to hepatocellular adenomas and carcinomas in rodents | Cancer; Gastrointestinal System Disease | Under Development | 0.2 | KE:716 | Increase, cell proliferation (hepatocytes) |
AOP:38 | Protein Alkylation leading to Liver Fibrosis | Gastrointestinal System Disease | WPHA/WNT Endorsed | 0.29 | KE:1492 | Tissue resident cell activation |
KE:1493 | Increased Pro-inflammatory mediators | |||||
AOP:39 | Covalent Binding, Protein, leading to Increase, Allergic Respiratory Hypersensitivity Response | Respiratory System Disease | Under Development | 0.4 | KE:398 | Activation, Dendritic Cells |
KE:272 | Activation/Proliferation, T-cells | |||||
AOP:41 | Sustained AhR Activation leading to Rodent Liver Tumours | Cancer; Gastrointestinal System Disease | Under Review | 0.6 | KE:854 | Alterations, Cellular proliferation / hyperplasia |
KE:853 | Changes/Inhibition, Cellular Homeostasis and Apoptosis | |||||
KE:139 | N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects | |||||
AOP:58 | NR1I3 (CAR) suppression leading to hepatic steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.06 | KE:451 | Inhibition, Mitochondrial fatty acid beta-oxidation |
AOP:60 | NR1I2 (Pregnane X Receptor, PXR) activation leading to hepatic steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.08 | KE:179 | Decreased, Mitochondrial fatty acid beta-oxidation |
AOP:64 | Glucocorticoid Receptor (GR) Mediated Adult Leydig Cell Dysfunction Leading to Decreased Male Fertility | Reproductive System Disease | - | 0.29 | KE:413 | Reduction, Testosterone synthesis in Leydig cells |
KE:496 | Increased apoptosis, decreased fetal/adult Leydig Cells | |||||
AOP:69 | Modulation of Adult Leydig Cell Function Subsequent to Decreased Cholesterol Synthesis or Transport in the Adult Leydig Cell | Reproductive System Disease | - | 0.2 | KE:645 | Decreased Cholesterol, Decreased Testosterone Production by Adult Leydig Cells |
AOP:77 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony death/failure 1 | Unclassified | - | 0.14 | KE:341 | Impairment, Learning and memory |
AOP:78 | Nicotinic acetylcholine receptor activation contributes to abnormal role change within the worker bee caste leading to colony death failure 1 | Unclassified | - | 0.12 | KE:341 | Impairment, Learning and memory |
AOP:80 | Nicotinic acetylcholine receptor activation contributes to accumulation of damaged mitochondrial DNA and leads to colony loss/failure | Unclassified | - | 0.12 | KE:664 | Overwhelmed, Mitochondrial DNA repair mechanisms |
AOP:87 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure | Unclassified | - | 0.12 | KE:341 | Impairment, Learning and memory |
AOP:88 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure via abnormal role change within caste | Unclassified | - | 0.14 | KE:341 | Impairment, Learning and memory |
AOP:89 | Nicotinic acetylcholine receptor activation followed by desensitization contributes to abnormal foraging and directly leads to colony loss/failure | Unclassified | - | 0.12 | KE:341 | Impairment, Learning and memory |
AOP:90 | Nicotinic acetylcholine receptor activation contributes to abnormal roll change within the worker bee caste leading to colony loss/failure 2 | Unclassified | - | 0.12 | KE:341 | Impairment, Learning and memory |
AOP:94 | Sodium channel inhibition leading to congenital malformations | Unclassified | - | 0.17 | KE:445 | Respiratory distress/arrest |
AOP:99 | Histamine (H2) receptor antagonism leading to reduced survival | Unclassified | - | 0.14 | KE:341 | Impairment, Learning and memory |
AOP:105 | Alpha2u-microglobulin cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) | Cancer; Urinary System Disease | - | 0.17 | KE:710 | Increase, Regenerative cell proliferation (tubular epithelial cells) |
AOP:107 | Constitutive androstane receptor activation leading to hepatocellular adenomas and carcinomas in the mouse and the rat | Cancer; Gastrointestinal System Disease | Under Review | 0.2 | KE:716 | Increase, cell proliferation (hepatocytes) |
AOP:108 | Inhibition of pyruvate dehydrogenase kinase leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal System Disease | - | 0.17 | KE:768 | Increase, Cytotoxicity |
AOP:109 | Cytotoxicity leading to bronchioloalveolar adenomas and carcinomas (in mouse) | Cancer; Respiratory System Disease | - | 0.2 | KE:734 | Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells) |
AOP:110 | Inhibition of iodide pump activity leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine System Disease | - | 0.14 | KE:739 | Increase, Hypertrophy and proliferation (follicular cell) |
AOP:114 | HPPD inhibition leading to corneal papillomas and carcinomas (in rat) | Cancer | - | 0.33 | KE:777 | Increase, Inflammation (corneal cells) |
KE:778 | Increase, Regenerative cell proliferation (corneal cells) | |||||
AOP:115 | Epithelial cytotoxicity leading to forestomach tumors (in mouse and rat) | Cancer | - | 0.4 | KE:149 | Increase, Inflammation |
KE:781 | Increase, Regenerative cell proliferation (forestomach epithelial cells) | |||||
AOP:116 | Cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) | Cancer; Urinary System Disease | - | 0.25 | KE:710 | Increase, Regenerative cell proliferation (tubular epithelial cells) |
AOP:117 | Androgen receptor activation leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal System Disease | Under Development | 0.25 | KE:716 | Increase, cell proliferation (hepatocytes) |
AOP:119 | Inhibition of thyroid peroxidase leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine System Disease | - | 0.14 | KE:739 | Increase, Hypertrophy and proliferation (follicular cell) |
AOP:128 | Kidney dysfunction by decreased thyroid hormone | Urinary System Disease | Under Development | 0.09 | KE:821 | Decreased, Sodium reabsorption |
AOP:136 | Intracellular Acidification Induced Olfactory Epithelial Injury Leading to Site of Contact Nasal Tumors | Benign Neoplasm; Respiratory System Disease | Under Review | 0.29 | KE:768 | Increase, Cytotoxicity |
KE:870 | Increase, Cell Proliferation | |||||
AOP:144 | Endocytic lysosomal uptake leading to liver fibrosis | Gastrointestinal System Disease | Under Review | 0.22 | KE:1494 | Leukocyte recruitment/activation |
KE:1493 | Increased Pro-inflammatory mediators | |||||
AOP:150 | Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF | Unclassified | WPHA/WNT Endorsed | 0.14 | KE:317 | Altered, Cardiovascular development/function |
AOP:154 | Inhibition of Calcineurin Activity Leading to Impaired T-Cell Dependent Antibody Response | Immune System Disease | WPHA/WNT Endorsed | 0.2 | KE:981 | Reduction, NFAT/AP-1 complex formation |
AOP:164 | Beta-2 adrenergic agonist activity leading to mesovarian leiomyomas in the rat and mouse | Cancer; Reproductive System Disease | - | 0.17 | KE:1042 | Proliferation/Clonal Expansion, smooth muscle |
AOP:167 | Early-life estrogen receptor activity leading to endometrial carcinoma in the mouse. | Reproductive System Disease; Cancer | - | 0.14 | KE:1067 | Proliferation/Clonal Expansion, aberrant basal cells |
AOP:207 | NADPH oxidase and P38 MAPK activation leading to reproductive failure in Caenorhabditis elegans | Reproductive System Disease | - | 0.38 | KE:1281 | Increased, DNA Damage-Repair |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1262 | Apoptosis | |||||
AOP:212 | Histone deacetylase inhibition leading to testicular atrophy | Reproductive System Disease | WPHA/WNT Endorsed | 0.17 | KE:1262 | Apoptosis |
AOP:213 | Inhibition of fatty acid beta oxidation leading to nonalcoholic steatohepatitis (NASH) | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.17 | KE:1115 | Increase, Reactive oxygen species |
AOP:220 | Cyp2E1 Activation Leading to Liver Cancer | Cancer; Gastrointestinal System Disease | WPHA/WNT Endorsed | 0.4 | KE:1393 | Hepatocytotoxicity |
KE:1394 | Induction, persistent proliferation/sustained proliferation | |||||
AOP:280 | α-diketone-induced bronchiolitis obliterans | Musculoskeletal System Disease; Respiratory System Disease | - | 0.14 | KE:149 | Increase, Inflammation |
AOP:299 | Deposition of energy leading to population decline via DNA oxidation and follicular atresia | Unclassified | - | 0.14 | KE:1115 | Increase, Reactive oxygen species |
AOP:311 | Deposition of energy leading to population decline via DNA oxidation and oocyte apoptosis | Unclassified | - | 0.14 | KE:1115 | Increase, Reactive oxygen species |
AOP:318 | Glucocorticoid Receptor activation leading to hepatic steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.2 | KE:860 | Decreased, Mitochondrial Fatty Acid Beta Oxidation |
AOP:322 | Alkylation of DNA leading to reduced sperm count | Reproductive System Disease | - | 0.2 | KE:155 | Inadequate DNA repair |
AOP:335 | AOP for urothelial carcinogenesis due to chemical cytotoxicity by mitochondrial impairment | Cancer; Urinary System Disease | - | 0.2 | KE:795 | Increase, Regenerative cell proliferation (urothelial cells) |
AOP:374 | Binding of Sars-CoV-2 spike protein to ACE 2 receptors expressed on brain cells (neuronal and non-neuronal) leads to neuroinflammation resulting in encephalitis | Nervous System Disease | Under Development | 0.25 | KE:352 | N/A, Neurodegeneration |
AOP:379 | Binding to ACE2 leading to thrombosis and disseminated intravascular coagulation | Cardiovascular System Disease | Under Development | 0.14 | KE:1869 | Diminished protective oxidative stress response |
AOP:383 | Inhibition of Angiotensin-converting enzyme 2 leading to liver fibrosis | Gastrointestinal System Disease | Under Development | 0.17 | KE:1115 | Increase, Reactive oxygen species |
AOP:386 | Deposition of ionizing energy leading to population decline via inhibition of photosynthesis | Reproductive System Disease | - | 0.12 | KE:1115 | Increase, Reactive oxygen species |
AOP:387 | Deposition of ionising energy leading to population decline via mitochondrial dysfunction | Reproductive System Disease | - | 0.12 | KE:1115 | Increase, Reactive oxygen species |
AOP:397 | Bulky DNA adducts leading to mutations | Genetic Disease | Under Development | 0.33 | KE:155 | Inadequate DNA repair |
AOP:399 | Inhibition of Fyna leading to increased mortality via decreased eye size (Microphthalmos) | Unclassified | - | 0.12 | KE:1821 | Decrease, Cell proliferation |
AOP:413 | Oxidation and antagonism of reduced glutathione leading to mortality via acute renal failure | Unclassified | - | 0.33 | KE:1115 | Increase, Reactive oxygen species |
KE:1607 | Increase, Necrosis | |||||
AOP:431 | Increased tumor necrosis factor (TNF) leading to increased risk of gestational diabetes mellitus (GDM) | Inherited Metabolic Disorder | - | 0.2 | KE:1952 | Abnormal, Glucose homeostasis |
AOP:432 | Deposition of Energy by Ionizing Radiation leading to Acute Myeloid Leukemia | Hematopoietic System Disease; Cancer | - | 0.27 | KE:870 | Increase, Cell Proliferation |
KE:1493 | Increased Pro-inflammatory mediators | |||||
KE:155 | Inadequate DNA repair | |||||
AOP:439 | Activation of the AhR leading to metastatic breast cancer | Thoracic Disease; Cancer | Under Development | 0.22 | KE:149 | Increase, Inflammation |
KE:1262 | Apoptosis | |||||
AOP:441 | Ionizing radiation-induced DNA damage leads to microcephaly via apoptosis and premature cell differentiation | Congenital Nervous System Abnormality; Nervous System Disease | - | 0.14 | KE:1262 | Apoptosis |
AOP:447 | Kidney failure induced by inhibition of mitochondrial electron transfer chain through apoptosis, inflammation and oxidative stress pathways | Urinary System Disease | - | 0.08 | KE:1097 | Occurrence, renal proximal tubular necrosis |
AOP:450 | Inhibition of AChE and activation of CYP2E1 leading to sensory axonal peripheral neuropathy and mortality | Nervous System Disease | - | 0.14 | KE:352 | N/A, Neurodegeneration |
AOP:452 | Adverse outcome pathway of PM-induced respiratory toxicity | Respiratory System Disease | - | 0.18 | KE:2011 | Emphysema |
KE:1262 | Apoptosis | |||||
AOP:456 | Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced cardiovascular toxicity | Unclassified | Under Review | 0.17 | KE:317 | Altered, Cardiovascular development/function |
AOP:460 | Antagonism of Smoothened receptor leading to orofacial clefting | Unclassified | Under Development | 0.22 | KE:1821 | Decrease, Cell proliferation |
KE:1262 | Apoptosis | |||||
AOP:470 | Deposition of energy leads to abnormal vascular remodeling | Cardiovascular System Disease | Under Review | 0.12 | KE:1493 | Increased Pro-inflammatory mediators |
AOP:478 | Deposition of energy leading to occurrence of cataracts | Nervous System Disease; Monogenic Disease | Under Review | 0.3 | KE:870 | Increase, Cell Proliferation |
KE:155 | Inadequate DNA repair | |||||
KE:1636 | Increase, Chromosomal aberrations | |||||
AOP:491 | Decrease, GLI1/2 target gene expression leads to orofacial clefting | Unclassified | Under Development | 0.33 | KE:1821 | Decrease, Cell proliferation |
KE:1262 | Apoptosis | |||||
AOP:492 | Glutathione conjugation leading to reproductive dysfunction via oxidative stress | Reproductive System Disease | - | 0.2 | KE:1115 | Increase, Reactive oxygen species |
AOP:493 | ERa inactivation alters AT expansion and functions and leads to insulin resistance and metabolically unhealthy obesity | Acquired Metabolic Disease | - | 0.2 | KE:1497 | Increased, recruitment of inflammatory cells |
KE:2119 | Insulin resistance, increased | |||||
AOP:495 | Androgen receptor activation leading to prostate cancer | Reproductive System Disease; Cancer | - | 0.22 | KE:854 | Alterations, Cellular proliferation / hyperplasia |
KE:1183 | Decreased, Apoptosis (Epithelial Cells) | |||||
AOP:521 | Essential element imbalance leads to reproductive failure via oxidative stress | Unclassified | - | 0.14 | KE:1115 | Increase, Reactive oxygen species |
AOP:529 | Perfluorooctanesulfonic acid (PFOS) binding to peroxisome proliferator-activated receptors (PPARs) causes dysregulation of lipid metabolism and subsequent liver steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.12 | KE:179 | Decreased, Mitochondrial fatty acid beta-oxidation |
AOP:539 | Decreased Sodium/Potassium ATPase activity leads to Heart failure | Cardiovascular System Disease | - | 0.14 | KE:2261 | Decreased, blood plasma volume |
AOP:544 | Inhibition of neuropathy target esterase leading to delayed neuropathy via increased inflammation | Nervous System Disease | - | 0.17 | KE:149 | Increase, Inflammation |
AOP:563 | Aryl hydrocarbon Receptor (AHR) activation causes Premature Ovarian Insufficiency via Bax mediated apoptosis | Reproductive System Disease; Endocrine System Disease | - | 0.17 | KE:1262 | Apoptosis |
AOP:569 | Decreased DNA methylation of FAM50B/PTCHD3 leading to IQ loss of children via PI3K-Akt pathway | Developmental Disorder Of Mental Health | - | 0.33 | KE:1115 | Increase, Reactive oxygen species |
KE:2195 | Increase, CNS Neural cell death |
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:12 | Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development leads to neurodegeneration with impairment in learning and memory in aging | Nervous System Disease; Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.25 | KE:341 | Impairment, Learning and memory |
KE:352 | N/A, Neurodegeneration | |||||
AOP:13 | Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities | Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.1 | KE:341 | Impairment, Learning and memory |
AOP:17 | Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress during brain development leads to impairment of learning and memory | Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.3 | KE:1492 | Tissue resident cell activation |
KE:1493 | Increased Pro-inflammatory mediators | |||||
KE:341 | Impairment, Learning and memory | |||||
AOP:19 | Androgen receptor antagonism leading to adverse effects in the male foetus (mammals) | Reproductive System Disease | - | 0.2 | KE:337 | N/A, Impairment of reproductive capacity |
AOP:40 | Covalent Protein binding leading to Skin Sensitisation | Integumentary System Disease | WPHA/WNT Endorsed | 0.8 | KE:827 | sensitisation, skin |
KE:826 | Activation, Keratinocytes | |||||
KE:398 | Activation, Dendritic Cells | |||||
KE:272 | Activation/Proliferation, T-cells | |||||
AOP:42 | Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | WPHA/WNT Endorsed | 0.12 | KE:402 | Cognitive function, decreased |
AOP:43 | Disruption of VEGFR Signaling Leading to Developmental Defects | Unclassified | WPHA/WNT Endorsed | 0.2 | KE:1001 | Increased, Developmental Defects |
AOP:48 | Binding of agonists to ionotropic glutamate receptors in adult brain causes excitotoxicity that mediates neuronal cell death, contributing to learning and memory impairment. | Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.22 | KE:341 | Impairment, Learning and memory |
KE:352 | N/A, Neurodegeneration | |||||
AOP:54 | Inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment | Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.1 | KE:341 | Impairment, Learning and memory |
AOP:124 | HMG-CoA reductase inhibition leading to decreased fertility | Reproductive System Disease | - | 0.17 | KE:330 | Decrease, Fertility |
AOP:134 | Sodium Iodide Symporter (NIS) Inhibition and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | - | 0.11 | KE:402 | Cognitive function, decreased |
AOP:139 | Alkylation of DNA leading to cancer 1 | Cancer | - | 0.5 | KE:885 | Increase, Cancer |
KE:155 | Inadequate DNA repair | |||||
AOP:148 | EGFR Activation Leading to Decreased Lung Function | Respiratory System Disease | Under Development | 0.25 | KE:1250 | Decrease, Lung function |
AOP:149 | Peptide Oxidation Leading to Hypertension | Cardiovascular System Disease | Under Development | 0.2 | KE:952 | Hypertension |
KE:933 | KE6 : Depletion, Nitric Oxide | |||||
AOP:173 | Substance interaction with the pulmonary resident cell membrane components leading to pulmonary fibrosis | Musculoskeletal System Disease; Respiratory System Disease | WPHA/WNT Endorsed | 0.25 | KE:1497 | Increased, recruitment of inflammatory cells |
KE:1458 | Pulmonary fibrosis | |||||
AOP:196 | Volatile Organic Chemicals Activate TRPA1 Receptor to Induce Sensory Pulmonary Irritation | Respiratory System Disease | - | 0.11 | KE:1226 | Increased Respiratory irritability and Chronic Cough, |
AOP:205 | AOP from chemical insult to cell death | Unclassified | - | 0.33 | KE:1263 | Necrosis |
KE:1262 | Apoptosis | |||||
AOP:206 | Peroxisome proliferator-activated receptors γ inactivation leading to lung fibrosis | Musculoskeletal System Disease; Respiratory System Disease | Under Development | 0.33 | KE:149 | Increase, Inflammation |
KE:1276 | Lung fibrosis | |||||
AOP:227 | NSAID induced PTGS1 inactivation to gastric ulcer | Gastrointestinal System Disease | - | 0.14 | KE:1385 | Activated, gastric ulcer formation |
AOP:228 | NSAID induced PTGS2 inactivation to gastric ulcer | Gastrointestinal System Disease | - | 0.2 | KE:1385 | Activated, gastric ulcer formation |
AOP:241 | Latent Transforming Growth Factor beta1 activation leads to pulmonary fibrosis | Musculoskeletal System Disease; Respiratory System Disease | - | 0.17 | KE:1458 | Pulmonary fibrosis |
AOP:245 | Reduction in photophosphorylation leading to growth inhibition in aquatic plants | Unclassified | - | 0.09 | KE:1521 | Decrease, Growth |
AOP:260 | CYP2E1 activation and formation of protein adducts leading to neurodegeneration | Nervous System Disease | - | 0.14 | KE:1514 | Neurodegeneration |
AOP:272 | Deposition of energy leading to lung cancer | Cancer | WPHA/WNT Endorsed | 0.57 | KE:870 | Increase, Cell Proliferation |
KE:1556 | Increase, lung cancer | |||||
KE:155 | Inadequate DNA repair | |||||
KE:1636 | Increase, Chromosomal aberrations | |||||
AOP:281 | Acetylcholinesterase Inhibition Leading to Neurodegeneration | Nervous System Disease | - | 0.1 | KE:352 | N/A, Neurodegeneration |
AOP:286 | Mitochondrial complex III antagonism leading to growth inhibition (1) | Unclassified | - | 0.5 | KE:1821 | Decrease, Cell proliferation |
KE:1521 | Decrease, Growth | |||||
AOP:287 | Mitochondrial complex III antagonism leading to growth inhibition (2) | Unclassified | - | 0.25 | KE:1521 | Decrease, Growth |
AOP:290 | Mitochondrial ATP synthase antagonism leading to growth inhibition (1) | Unclassified | - | 0.5 | KE:1821 | Decrease, Cell proliferation |
KE:1521 | Decrease, Growth | |||||
AOP:291 | Mitochondrial ATP synthase antagonism leading to growth inhibition (2) | Unclassified | - | 0.25 | KE:1521 | Decrease, Growth |
AOP:293 | Increased DNA damage leading to increased risk of breast cancer | Genetic Disease; Thoracic Disease; Cancer | Under Development | 0.56 | KE:1193 | N/A, Breast Cancer |
KE:1492 | Tissue resident cell activation | |||||
KE:1182 | Increase, Cell Proliferation (Epithelial Cells) | |||||
KE:1494 | Leukocyte recruitment/activation | |||||
KE:1493 | Increased Pro-inflammatory mediators | |||||
AOP:294 | Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer | Genetic Disease; Thoracic Disease; Cancer | Under Development | 0.56 | KE:1193 | N/A, Breast Cancer |
KE:1492 | Tissue resident cell activation | |||||
KE:1182 | Increase, Cell Proliferation (Epithelial Cells) | |||||
KE:1494 | Leukocyte recruitment/activation | |||||
KE:1493 | Increased Pro-inflammatory mediators | |||||
AOP:296 | Oxidative DNA damage leading to chromosomal aberrations and mutations | Genetic Disease; Chromosomal Disease | WPHA/WNT Endorsed | 0.4 | KE:155 | Inadequate DNA repair |
KE:1636 | Increase, Chromosomal aberrations | |||||
AOP:300 | Thyroid Receptor Antagonism and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | Under Development | 0.2 | KE:402 | Cognitive function, decreased |
AOP:302 | Lung surfactant function inhibition leading to decreased lung function | Respiratory System Disease | Under Development | 0.2 | KE:1250 | Decrease, Lung function |
AOP:347 | Toll-like receptor 4 activation and peroxisome proliferator-activated receptor gamma inactivation leading to pulmonary fibrosis | Musculoskeletal System Disease; Respiratory System Disease | - | 0.11 | KE:1458 | Pulmonary fibrosis |
AOP:382 | Angiotensin II type 1 receptor (AT1R) agonism leading to lung fibrosis | Musculoskeletal System Disease; Respiratory System Disease | Under Development | 0.33 | KE:1115 | Increase, Reactive oxygen species |
KE:1276 | Lung fibrosis | |||||
AOP:384 | Hyperactivation of ACE/Ang-II/AT1R axis leading to chronic kidney disease | Urinary System Disease | - | 0.33 | KE:1115 | Increase, Reactive oxygen species |
KE:1603 | Chronic kidney disease | |||||
AOP:392 | Decreased fibrinolysis and activated bradykinin system leading to hyperinflammation | Unclassified | Under Development | 0.4 | KE:1868 | Hyperinflammation |
KE:1497 | Increased, recruitment of inflammatory cells | |||||
AOP:405 | Organo-Phosphate Chemicals induced inhibition of AChE leading to impaired cognitive function | Cognitive Disorder | - | 0.2 | KE:402 | Cognitive function, decreased |
AOP:406 | SARS-CoV-2 infection leading to hyperinflammation | Unclassified | - | 0.33 | KE:1868 | Hyperinflammation |
KE:1869 | Diminished protective oxidative stress response | |||||
AOP:411 | Oxidative stress Leading to Decreased Lung Function | Respiratory System Disease | - | 0.25 | KE:1250 | Decrease, Lung function |
AOP:414 | Aryl hydrocarbon receptor activation leading to lung fibrosis through TGF-β dependent fibrosis toxicity pathway | Musculoskeletal System Disease; Respiratory System Disease | - | 0.2 | KE:1276 | Lung fibrosis |
AOP:415 | Aryl hydrocarbon receptor activation leading to lung fibrosis through IL-6 toxicity pathway | Musculoskeletal System Disease; Respiratory System Disease | - | 0.2 | KE:1276 | Lung fibrosis |
AOP:416 | Aryl hydrocarbon receptor activation leading to lung cancer through IL-6 toxicity pathway | Cancer | - | 0.5 | KE:1669 | Increased, DNA damage and mutation |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1670 | Lung cancer | |||||
AOP:417 | Aryl hydrocarbon receptor activation leading to lung cancer through AHR-ARNT toxicity pathway | Cancer | - | 0.4 | KE:1669 | Increased, DNA damage and mutation |
KE:1670 | Lung cancer | |||||
AOP:418 | Aryl hydrocarbon receptor activation leading to impaired lung function through AHR-ARNT toxicity pathway | Respiratory System Disease | - | 0.4 | KE:1115 | Increase, Reactive oxygen species |
KE:1250 | Decrease, Lung function | |||||
AOP:419 | Aryl hydrocarbon receptor activation leading to impaired lung function through P53 toxicity pathway | Respiratory System Disease | - | 0.5 | KE:1250 | Decrease, Lung function |
KE:1262 | Apoptosis | |||||
AOP:420 | Aryl hydrocarbon receptor activation leading to lung cancer through sustained NRF2 toxicity pathway | Cancer | - | 0.5 | KE:870 | Increase, Cell Proliferation |
KE:1670 | Lung cancer | |||||
AOP:424 | Oxidative stress Leading to Decreased Lung Function via CFTR dysfunction | Respiratory System Disease | - | 0.17 | KE:1250 | Decrease, Lung function |
AOP:425 | Oxidative Stress Leading to Decreased Lung Function via Decreased FOXJ1 | Respiratory System Disease | - | 0.17 | KE:1250 | Decrease, Lung function |
AOP:430 | Binding of SARS-CoV-2 to ACE2 leads to viral infection proliferation | Viral Infectious Disease | Under Development | 0.2 | KE:1939 | Viral infection and host-to-host transmission, proliferated |
AOP:442 | Binding to voltage gate sodium channels during development leads to cognitive impairment | Cognitive Disorder | Under Review | 0.14 | KE:402 | Cognitive function, decreased |
AOP:451 | Interaction with lung resident cell membrane components leads to lung cancer | Cancer | - | 0.56 | KE:1669 | Increased, DNA damage and mutation |
KE:870 | Increase, Cell Proliferation | |||||
KE:1670 | Lung cancer | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1497 | Increased, recruitment of inflammatory cells | |||||
AOP:457 | Succinate dehydrogenase inhibition leading to increased insulin resistance through reduction in circulating thyroxine | Inherited Metabolic Disorder | - | 0.17 | KE:2119 | Insulin resistance, increased |
AOP:458 | AhR activation in the liver leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | - | 0.12 | KE:402 | Cognitive function, decreased |
AOP:459 | AhR activation in the thyroid leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | - | 0.11 | KE:402 | Cognitive function, decreased |
AOP:468 | Binding of SARS-CoV-2 to ACE2 leads to hyperinflammation (via cell death) | Unclassified | - | 0.25 | KE:1868 | Hyperinflammation |
KE:1497 | Increased, recruitment of inflammatory cells | |||||
AOP:474 | Succinate dehydrogenase inactivation leads to cancer by promoting EMT | Cancer | Under Development | 0.2 | KE:885 | Increase, Cancer |
AOP:475 | Binding of chemicals to ionotropic glutamate receptors leads to impairment of learning and memory via loss of drebrin from dendritic spines of neurons | Developmental Disorder Of Mental Health | Under Development | 0.12 | KE:341 | Impairment, Learning and memory |
AOP:483 | Deposition of Energy Leading to Learning and Memory Impairment | Developmental Disorder Of Mental Health | Under Review | 0.25 | KE:1492 | Tissue resident cell activation |
KE:341 | Impairment, Learning and memory | |||||
AOP:485 | Thyroid hormone antagonism leading to impaired oligodendrocyte maturation during development and subsequent decreased cognition | Cognitive Disorder | - | 0.14 | KE:402 | Cognitive function, decreased |
AOP:486 | Binding to the extracellular protein laminin leading to decreased cognitive function | Cognitive Disorder | - | 0.14 | KE:402 | Cognitive function, decreased |
AOP:490 | Co-activation of IP3R and RyR leads to reduced IQ through non-cholinergic mechanisms | Developmental Disorder Of Mental Health | - | 0.09 | KE:341 | Impairment, Learning and memory |
AOP:497 | ERa inactivation alters mitochondrial functions and insulin signalling in skeletal muscle and leads to insulin resistance and metabolic syndrome | Inherited Metabolic Disorder; Disease Of Metabolism | - | 0.5 | KE:1115 | Increase, Reactive oxygen species |
KE:179 | Decreased, Mitochondrial fatty acid beta-oxidation | |||||
KE:2145 | Metabolic syndrome | |||||
KE:2119 | Insulin resistance, increased | |||||
AOP:498 | Increased LCN2/iron complex leading to neurological disorders | Nervous System Disease | - | 0.5 | KE:191 | Neuronal dysfunction |
KE:2150 | Neurological disorder | |||||
AOP:499 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via disrupted neurotransmitter release | Developmental Disorder Of Mental Health | - | 0.25 | KE:341 | Impairment, Learning and memory |
AOP:500 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via ROS and apoptosis | Developmental Disorder Of Mental Health | - | 0.57 | KE:1115 | Increase, Reactive oxygen species |
KE:1262 | Apoptosis | |||||
KE:341 | Impairment, Learning and memory | |||||
KE:352 | N/A, Neurodegeneration | |||||
AOP:501 | Excessive iron accumulation leading to neurological disorders | Nervous System Disease | - | 0.25 | KE:2150 | Neurological disorder |
AOP:520 | Retinoic acid receptor agonism during neurodevelopment leading to impaired learning and memory | Developmental Disorder Of Mental Health | - | 0.2 | KE:341 | Impairment, Learning and memory |
AOP:525 | Reduced oligodendrocyte differentiation during neurodevelopment leading to impaired learning and memory | Developmental Disorder Of Mental Health | - | 0.08 | KE:341 | Impairment, Learning and memory |
AOP:533 | Retinoic acid receptor antagonism during neurodevelopment leading to impaired learning and memory | Developmental Disorder Of Mental Health | - | 0.17 | KE:341 | Impairment, Learning and memory |
AOP:534 | Succinate dehydrogenase (SDH) inhibition leads to cancer through oxidative stress | Cancer | - | 0.5 | KE:1115 | Increase, Reactive oxygen species |
KE:885 | Increase, Cancer | |||||
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:535 | Binding and activation of GPER leading to learning and memory impairments | Developmental Disorder Of Mental Health | - | 0.22 | KE:1262 | Apoptosis |
KE:341 | Impairment, Learning and memory | |||||
AOP:546 | Succinate dehydrogenase inactivation leads to cancer through hypoxic-like mechanisms | Cancer | - | 0.2 | KE:885 | Increase, Cancer |
AOP:573 | Inhibition, cytochrome oxidase leads to Increased, pulmonary edema | Respiratory System Disease | - | 0.33 | KE:2316 | Increased, pulmonary edema |
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:62 | AKT2 activation leading to hepatic steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.25 | KE:486 | systemic inflammation leading to hepatic steatosis |
AOP:118 | Chronic cytotoxicity leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal System Disease | - | 0.5 | KE:786 | Increase, Cytotoxicity (hepatocytes) |
KE:787 | Increase, Regenerative cell proliferation (hepatocytes) | |||||
AOP:121 | Urinary bladder calculi leading to urothelial papillomas and carcinomas (in mouse and rat) | Cancer; Urinary System Disease | - | 0.4 | KE:795 | Increase, Regenerative cell proliferation (urothelial cells) |
KE:793 | Increase, Urinary bladder calculi | |||||
AOP:209 | Perturbation of cholesterol and glutathione homeostasis leading to hepatotoxicity: Integrated multi-OMICS approach for building AOP | Gastrointestinal System Disease | - | 0.25 | KE:1287 | Glutathione synthesis |
KE:1286 | Down Regulation, GSS and GSTs gene | |||||
AOP:282 | Adverse outcome pathway on photochemical toxicity initiated by light exposure | Unclassified | Under Review | 0.25 | KE:1115 | Increase, Reactive oxygen species |
AOP:298 | Increase in reactive oxygen species (ROS) leading to human treatment-resistant gastric cancer via chronic ROS | Cancer; Gastrointestinal System Disease | Under Review | 0.33 | KE:1115 | Increase, Reactive oxygen species |
KE:1753 | Chronic reactive oxygen species | |||||
AOP:327 | Excessive reactive oxygen species production leading to mortality (1) | Unclassified | - | 0.2 | KE:1115 | Increase, Reactive oxygen species |
AOP:328 | Excessive reactive oxygen species production leading to mortality (2) | Unclassified | - | 0.2 | KE:1115 | Increase, Reactive oxygen species |
AOP:329 | Excessive reactive oxygen species production leading to mortality (3) | Unclassified | - | 0.2 | KE:1115 | Increase, Reactive oxygen species |
AOP:330 | Excessive reactive oxygen species production leading to mortality (4) | Unclassified | - | 0.2 | KE:1115 | Increase, Reactive oxygen species |
AOP:409 | Frustrated phagocytosis leads to malignant mesothelioma | Cancer | - | 0.62 | KE:1669 | Increased, DNA damage and mutation |
KE:870 | Increase, Cell Proliferation | |||||
KE:1668 | Frustrated phagocytosis | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1497 | Increased, recruitment of inflammatory cells | |||||
AOP:423 | Toxicological mechanisms of hepatocyte apoptosis through the PARP1 dependent cell death pathway | Unclassified | - | 0.17 | KE:1115 | Increase, Reactive oxygen species |
AOP:438 | reactive oxygen species generation leading to increased cardiovascular morbidity and mortality | Cardiovascular System Disease | - | 0.08 | KE:1115 | Increase, Reactive oxygen species |
AOP:443 | DNA damage and mutations leading to Metastatic Breast Cancer | Thoracic Disease; Cancer | Under Development | 0.3 | KE:1669 | Increased, DNA damage and mutation |
KE:1554 | Increase Chromosomal Aberrations | |||||
KE:155 | Inadequate DNA repair | |||||
AOP:446 | PM-related Adverse outcome pathway frameworks on various systems | Respiratory System Disease | - | 0.35 | KE:1262 | Apoptosis |
KE:1458 | Pulmonary fibrosis | |||||
KE:149 | Increase, Inflammation | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1250 | Decrease, Lung function | |||||
KE:1993 | Increase, Pneumonia | |||||
KE:1497 | Increased, recruitment of inflammatory cells | |||||
AOP:448 | ROS, inflammation, and activation of nAChR lead to increased incidence of cardiovascular morbidity and mortality | Cardiovascular System Disease | - | 0.06 | KE:1115 | Increase, Reactive oxygen species |
AOP:453 | Reactive oxygen species and subsequent oxidative stress lead to increased incidence of digestive morbidity and mortality in the general population | Gastrointestinal System Disease | - | 0.15 | KE:1995 | Abnormal lipid metabolism |
KE:1115 | Increase, Reactive oxygen species | |||||
AOP:463 | The AOP framwork on silica nanopariticles induced hepatoxicity | Gastrointestinal System Disease | - | 0.27 | KE:149 | Increase, Inflammation |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1262 | Apoptosis | |||||
AOP:469 | Reactive oxygen speicies overproduction leading to increased digestive morbidity and mortality in generation population | Gastrointestinal System Disease | - | 0.15 | KE:1995 | Abnormal lipid metabolism |
KE:1115 | Increase, Reactive oxygen species | |||||
AOP:472 | DNA adduct formation leading to kidney failure | Urinary System Disease | - | 0.33 | KE:149 | Increase, Inflammation |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1097 | Occurrence, renal proximal tubular necrosis | |||||
AOP:511 | The AOP framework on ROS-mediated oxidative stress induced vascular disrupting effects | Cardiovascular System Disease | - | 0.06 | KE:1115 | Increase, Reactive oxygen species |
AOP:540 | Oxidative Stress in the Fish Ovary Leads to Reproductive Impairment via Reduced Vitellogenin Production | Unclassified | - | 0.22 | KE:1115 | Increase, Reactive oxygen species |
KE:1262 | Apoptosis | |||||
AOP:541 | Excessive ROS generation leading to increased incidence of vascular calcification by VSMC phenotype switching | Cardiovascular System Disease | - | 0.15 | KE:1115 | Increase, Reactive oxygen species |
KE:1493 | Increased Pro-inflammatory mediators |
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:263 | Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased cell proliferation | Unclassified | WPHA/WNT Endorsed | 0.75 | KE:1821 | Decrease, Cell proliferation |
KE:1521 | Decrease, Growth | |||||
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:264 | Uncoupling of oxidative phosphorylation leading to growth inhibition via ATP depletion associated cell death | Unclassified | Under Development | 0.5 | KE:1521 | Decrease, Growth |
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:265 | Uncoupling of oxidative phosphorylation leading to growth inhibition via increased cytosolic calcium | Unclassified | Under Development | 0.5 | KE:1521 | Decrease, Growth |
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:266 | Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased Na-K ATPase activity | Unclassified | Under Development | 0.33 | KE:1521 | Decrease, Growth |
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:267 | Uncoupling of oxidative phosphorylation leading to growth inhibition via glucose depletion | Unclassified | Under Development | 0.6 | KE:1821 | Decrease, Cell proliferation |
KE:1521 | Decrease, Growth | |||||
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:268 | Uncoupling of oxidative phosphorylation leading to growth inhibition via mitochondrial swelling | Unclassified | Under Development | 0.5 | KE:1521 | Decrease, Growth |
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:303 | Frustrated phagocytosis-induced lung cancer | Cancer | Under Development | 0.86 | KE:1669 | Increased, DNA damage and mutation |
KE:870 | Increase, Cell Proliferation | |||||
KE:1670 | Lung cancer | |||||
KE:1668 | Frustrated phagocytosis | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1497 | Increased, recruitment of inflammatory cells | |||||
AOP:324 | Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage and cell death | Unclassified | - | 0.5 | KE:1115 | Increase, Reactive oxygen species |
KE:1521 | Decrease, Growth | |||||
AOP:325 | Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and cell death | Unclassified | - | 0.5 | KE:1115 | Increase, Reactive oxygen species |
KE:1521 | Decrease, Growth | |||||
AOP:326 | Excessive reactive oxygen species leading to growth inhibition via protein oxidation and cell death | Unclassified | - | 0.5 | KE:1115 | Increase, Reactive oxygen species |
KE:1521 | Decrease, Growth | |||||
AOP:331 | Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage and reduced cell proliferation | Unclassified | - | 0.5 | KE:1821 | Decrease, Cell proliferation |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1521 | Decrease, Growth | |||||
AOP:332 | Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and reduced cell proliferation | Unclassified | - | 0.6 | KE:1821 | Decrease, Cell proliferation |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1521 | Decrease, Growth | |||||
AOP:333 | Excessive reactive oxygen species leading to growth inhibition via uncoupling of oxidative phosphorylation | Unclassified | - | 0.8 | KE:1821 | Decrease, Cell proliferation |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1521 | Decrease, Growth | |||||
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:488 | Increased reactive oxygen species production leading to decreased cognitive function | Cognitive Disorder | - | 0.43 | KE:1115 | Increase, Reactive oxygen species |
KE:1869 | Diminished protective oxidative stress response | |||||
KE:402 | Cognitive function, decreased | |||||
AOP:505 | Reactive Oxygen Species (ROS) formation leads to cancer via inflammation pathway | Cancer | - | 0.6 | KE:149 | Increase, Inflammation |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:885 | Increase, Cancer | |||||
AOP:513 | Reactive Oxygen (ROS) formation leads to cancer via Peroxisome proliferation-activated receptor (PPAR) pathway | Cancer | - | 0.4 | KE:1115 | Increase, Reactive oxygen species |
KE:885 | Increase, Cancer |
TICToK is a database of tattoo ink chemicals compiled from different regulatory resources. The authors are not liable for any inaccuracies or omissions of any chemicals in this resource. Importantly, our sole goal to build this resource on tattoo ink chemicals is to enable future basic research on this topic, and it does not necessarily reflect the views or objectives of our employers or funders.